IUI vs IVF After 38: When Lower Upfront Cost May Lose to Time, Success Rates, and PGT Embryo Testing Options

As a reproductive medicine physician, I usually explain it this way: IUI and IVF are not simply two different prices for the same service. They are different strategies. IUI tries to slightly improve the odds of natural conception by placing prepared sperm closer to the egg around ovulation. IVF creates embryos in the laboratory, allows embryologists and physicians to observe fertilization and embryo development, and may offer preimplantation genetic testing for aneuploidy, known as PGT-A, to help identify embryos with the correct number of chromosomes before transfer. This additional information can be especially relevant after 38, when the percentage of chromosomally abnormal eggs and embryos rises sharply.

This article compares IUI and IVF after age 38 from a practical perspective: time, success rates, cost, miscarriage risk, diagnostic information, and embryo testing options. The goal is not to say that every patient over 38 must go directly to IVF. Some people are still reasonable candidates for IUI. However, the decision should be made with a realistic understanding of age-related fertility, not only the price of one treatment cycle.

Why age 38 is an important fertility turning point

Female fertility does not suddenly disappear at 38, but the decline becomes more clinically important. Ovarian reserve, which refers to the number of eggs remaining, generally decreases with age. Even more importantly, egg quality declines. “Egg quality” often refers to the likelihood that an egg can mature normally, fertilize, develop into a healthy embryo, implant, and result in a live birth. A major part of egg quality is chromosomal normality. Eggs are more likely to have errors in chromosome separation as age increases. When these eggs fertilize, the resulting embryos may have too many or too few chromosomes, a condition called aneuploidy.

Aneuploid embryos frequently fail to implant. If they do implant, they are more likely to end in miscarriage. This is why a person may still ovulate regularly at 39 or 40 yet experience months of negative pregnancy tests or repeated early pregnancy losses. The cycle may look normal from the outside, but the embryo may not have the genetic potential to continue developing.

Time also matters because the decline is not linear. The difference between 34 and 35 is usually less dramatic than the difference between 39 and 40, or 41 and 42. A six-month trial of low-success treatment may be reasonable at younger ages, but after 38, six months can represent a meaningful portion of the remaining reproductive window using one’s own eggs.

What IUI can and cannot do

IUI is a relatively simple fertility treatment. The patient may take oral medications such as letrozole or clomiphene citrate, sometimes injectable gonadotropins, to encourage the development of one or more follicles. Ultrasound monitoring may be used to track follicle growth. Ovulation may occur naturally or be triggered with an hCG injection. On the day of insemination, a semen sample is washed and concentrated, then placed through a thin catheter into the uterus.

IUI can help in certain situations: mild male factor infertility, cervical factor issues, sexual dysfunction, use of donor sperm, unexplained infertility, or mild ovulation problems. It may reduce the distance sperm must travel and improve timing. However, IUI does not correct blocked fallopian tubes, severe male factor infertility, severe endometriosis, very low ovarian reserve, or age-related chromosomal abnormalities in eggs.

The most important limitation after 38 is that IUI cannot tell us whether fertilization occurred, whether an embryo formed, whether that embryo developed normally, or whether it had the correct number of chromosomes. Each cycle remains largely a “black box.” If pregnancy does not occur, we often do not know whether the issue was egg quality, sperm function, fertilization failure, tubal transport, embryo development, implantation, or simply chance.

What IVF adds beyond a higher price

IVF is more complex and more expensive, but it offers several advantages that become increasingly valuable with age. During IVF, the ovaries are stimulated with injectable medications to mature multiple eggs. The eggs are retrieved under ultrasound guidance, fertilized in the laboratory with sperm, and cultured for several days. Embryos may be transferred fresh or frozen for later transfer. If appropriate, embryos can be biopsied for PGT-A, then frozen while results are pending.

IVF does not make eggs younger. It cannot turn an aneuploid egg into a euploid embryo. But IVF can improve efficiency by allowing multiple eggs to be retrieved in one cycle, by confirming whether fertilization occurs, by observing embryo development, and by selecting embryos for transfer based on morphology and, when used, genetic testing. For patients after 38, this ability to gather information quickly is often one of IVF’s greatest strengths.

For example, after an IVF cycle, we may learn that ovarian response is lower than expected, that few mature eggs are retrieved, that fertilization is poor, that embryos arrest before the blastocyst stage, or that most blastocysts are aneuploid. This information may feel difficult emotionally, but it helps guide next steps. Without IVF, the same patient might spend many months on IUI cycles without knowing where the process is failing.

Success rates after 38: why “per cycle” numbers can be misleading

Success rates vary by clinic, diagnosis, ovarian reserve, sperm quality, treatment protocol, body mass index, uterine factors, prior pregnancy history, and whether donor eggs are used. Still, broad patterns are consistent: IUI success declines substantially after 38, while IVF generally offers higher success per treatment attempt, especially when a euploid embryo is available for transfer.

For IUI, pregnancy rates per cycle in women 38 to 40 are often quoted in the single digits to low teens, depending on the population and medications used. Live birth rates are lower than pregnancy rates because miscarriage risk is higher with age. By 41 to 42, IUI live birth rates are often quite low, and after 43, success with IUI using one’s own eggs is usually very limited.

For IVF, the relevant numbers can be presented in several ways: live birth per egg retrieval, live birth per embryo transfer, cumulative live birth after using all embryos from one retrieval, or live birth per euploid embryo transfer. These are not interchangeable. A patient may have a high chance of live birth if she has a euploid embryo to transfer, but the chance of obtaining a euploid embryo at age 40 or 42 may be much lower than at age 32.

The hidden cost of “just trying a few IUIs”

The lower upfront cost of IUI is real. In many settings, one IUI cycle costs a fraction of one IVF cycle. For patients paying out of pocket, this difference is significant. However, fertility treatment after 38 should be evaluated not only by price per cycle, but by cost per live birth and time to live birth.

Suppose a patient completes three IUI cycles over three to four months. If each cycle has a modest chance of live birth, the cumulative chance may still be limited. If those cycles fail, she may then proceed to IVF at an older age than when she started. During that time, ovarian reserve may decline, and the probability of producing a euploid embryo may decrease. The money spent on IUI is not necessarily wasted if it succeeds, but if it does not, the patient has paid both financially and biologically.

This does not mean IUI should never be tried after 38. It means the trial should be intentional and time-limited. A common approach is to consider one to three IUI cycles only if ovarian reserve is reassuring, tubes are open, sperm parameters are adequate, there is no severe endometriosis or pelvic disease, and the patient understands the lower success rate. If these conditions are not met, moving directly to IVF is often more efficient.

PGT-A: what embryo testing can offer after 38

Preimplantation genetic testing for aneuploidy, or PGT-A, is an embryo screening method used during IVF. Typically, embryos are grown to the blastocyst stage, usually day 5, 6, or sometimes 7 after fertilization. A few cells are biopsied from the trophectoderm, the part of the embryo that later contributes to the placenta. The embryo is frozen while the sample is analyzed. The test estimates whether the embryo is euploid, meaning it has the expected number of chromosomes; aneuploid, meaning it has missing or extra chromosomes; or sometimes mosaic, meaning both normal and abnormal cell lines are detected in the sample.

PGT-A does not improve the genetics of an embryo. It is a selection tool, not a repair tool. Its potential benefits include reducing the likelihood of transferring an embryo that cannot implant, lowering miscarriage risk related to aneuploidy, shortening time to pregnancy by prioritizing embryos more likely to result in live birth, and supporting single embryo transfer to reduce twin and higher-order multiple pregnancy risks.

After age 38, PGT-A becomes a more common discussion because the proportion of aneuploid embryos is higher. If several blastocysts are available, PGT-A may help choose which embryo to transfer first. For patients who have had recurrent pregnancy loss, repeated failed transfers, or a strong desire to reduce miscarriage risk, embryo testing may be particularly appealing.

However, PGT-A has limitations. Not every IVF cycle produces blastocysts suitable for biopsy. A patient with very few embryos may face a difficult decision about whether testing adds value or risks having no embryo transfer if results are abnormal. PGT-A results are highly useful but not perfect; false positives, false negatives, mosaicism, and embryo self-correction debates are part of modern reproductive medicine. A euploid result improves the chance of success but does not guarantee pregnancy. Uterine factors, embryo handling, laboratory quality, immune and endocrine factors, and chance still matter.

Why PGT is not available with IUI

One of the clearest differences between IUI and IVF is that IUI does not create embryos outside the body. Fertilization, if it occurs, happens in the fallopian tube. Early embryo development occurs inside the reproductive tract. Because there is no embryo in the laboratory, there is no opportunity to biopsy and test it before pregnancy. Therefore, patients who want embryo chromosome screening before transfer must use IVF.

This distinction is particularly important for patients after 38 who have a history of miscarriages or who want to reduce the chance of transferring an aneuploid embryo. With IUI, pregnancy can occur naturally, but if the embryo is chromosomally abnormal, the result may be a negative test, biochemical pregnancy, early miscarriage, or less commonly an ongoing pregnancy with a chromosomal condition. Prenatal testing during pregnancy can provide information later, but it does not prevent the initial implantation of an aneuploid embryo.

Who may still consider IUI after 38?

IUI may still be reasonable for selected patients between 38 and 40, and occasionally beyond, depending on personal circumstances. A good candidate may have regular ovulation or a mild ovulation issue, at least one open fallopian tube, reassuring ovarian reserve testing, a normal uterine cavity, adequate sperm parameters after washing, no severe endometriosis, and a relatively short duration of infertility. IUI may also be appropriate when using donor sperm and there is no known female-factor infertility.

Financial limitations also matter. Not everyone can access IVF. Some insurance plans require IUI before IVF coverage. Some patients prefer to try the least invasive option first. These values are valid. Medicine should not ignore emotional readiness, cultural beliefs, relationship dynamics, or affordability. The key is to avoid open-ended IUI attempts when the probability is low. A plan such as “we will try up to two well-timed IUIs, then reassess immediately” is very different from “we will keep trying IUI for a year.”

When IVF is usually favored after 38

IVF is often favored when the patient is 38 or older and has additional factors that lower the chance of IUI success. These include diminished ovarian reserve, low anti-Müllerian hormone, elevated day-3 FSH, low antral follicle count, blocked or damaged fallopian tubes, moderate to severe endometriosis, significant male factor infertility, long duration of infertility, prior failed IUI cycles, recurrent pregnancy loss, or a strong preference for PGT-A.

IVF may also be favored when family-building goals include more than one child. For a 39-year-old who wants two children, embryo banking can be an important discussion. If she conceives through IUI at 39 and delivers at 40, trying for a second child with her own eggs at 41 or 42 may be significantly harder. IVF may allow creation and freezing of embryos at the current age, potentially preserving some reproductive opportunity for later. This does not guarantee a second child, but it can be strategically valuable.

Miscarriage risk and the emotional side of treatment choice

Pregnancy loss is emotionally devastating at any age, but after 38 it can also consume time that is difficult to recover. Because aneuploidy is a major cause of miscarriage, the rising rate of chromosomally abnormal embryos contributes to higher miscarriage rates with age. IUI cannot screen embryos before conception. IVF with PGT-A may reduce miscarriage risk by helping avoid transfer of clearly aneuploid embryos, although it cannot eliminate all losses.

Some patients value the chance to conceive in a less medicalized way and accept the risk of miscarriage. Others strongly prefer to reduce uncertainty where possible, even if that means injections, procedures, and higher costs. Neither preference is wrong. The role of the fertility team is to provide realistic probabilities, explain trade-offs, and support a decision that fits the patient’s medical situation and values.

Multiple pregnancy risk: IUI is not always “simpler” in outcome

A common misconception is that IUI is always safer because it is less invasive. The procedure itself is simpler than IVF, but medication-stimulated IUI can carry a risk of twins or higher-order multiples if multiple follicles ovulate. Multiple pregnancy increases the risk of preterm birth, gestational diabetes, hypertension, cesarean delivery, neonatal intensive care admission, and long-term health concerns for babies.

IVF, especially with single embryo transfer, can often control multiple pregnancy risk more effectively. PGT-A may make single embryo transfer more acceptable to patients who fear “wasting time,” because the selected embryo has a higher probability of implantation than an untested embryo chosen by appearance alone. Still, even single embryo transfer can rarely result in identical twins, so the risk is reduced but not zero.

Testing before choosing IUI or IVF

Before deciding between IUI and IVF, a complete fertility evaluation is essential. For the female partner or person carrying the pregnancy, this often includes ovarian reserve testing with AMH, antral follicle count by ultrasound, and sometimes day-3 FSH and estradiol. Uterine evaluation may include saline infusion sonogram, hysteroscopy, or other imaging when indicated. Tubal assessment with hysterosalpingogram or similar testing is important before IUI because IUI requires at least one functional fallopian tube. For the male partner or sperm source, semen analysis is necessary, and sometimes advanced sperm testing or urology evaluation is recommended.

General health also matters. Thyroid function, prolactin, hemoglobin A1c, body weight, blood pressure, medications, genetic carrier screening, vaccination status, and lifestyle factors should be reviewed. Optimizing health before pregnancy can improve safety and outcomes regardless of whether conception occurs through IUI, IVF, or spontaneously.

A practical decision framework after 38

When counseling a patient over 38, I often recommend thinking in terms of scenarios rather than a single universal rule. If you are 38 or 39, have open tubes, normal sperm, reassuring ovarian reserve, no major infertility diagnosis, and are comfortable with a short trial, one or two IUIs may be reasonable. If you are 40 or older, have been trying for a long time, have diminished ovarian reserve, have had miscarriages, or want PGT-A, IVF is often the more efficient path. If you are 42 or older, the discussion should be especially direct about the low probability of success with IUI and the possibility that even IVF with own eggs may require multiple retrievals or may not produce a euploid embryo.

For patients in their early 40s, it is also important to discuss donor eggs without implying that it is the only option or that patients must choose it immediately. Donor egg IVF has much higher success rates because embryo potential is more closely related to egg age than uterine age. Some patients want to try with their own eggs first, and that is reasonable when they understand the odds. Others choose donor eggs sooner to improve the chance of pregnancy and reduce repeated treatment failure. The right answer is personal.

Cost comparison: upfront price versus value of time

Financially, IUI can be attractive because a cycle may cost far less than IVF. But the total cost depends on how many cycles are attempted, medication doses, monitoring, sperm preparation, donor sperm costs if applicable, pregnancy losses, time away from work, travel, and eventual IVF if IUI fails. IVF has a higher upfront price, especially when medications, anesthesia, ICSI, embryo freezing, storage, and PGT-A are included. Yet IVF may reduce the number of months spent trying lower-yield options and may provide information that prevents repeated ineffective treatment.

Insurance coverage can reverse the decision. Some patients have excellent IUI coverage but limited IVF benefits. Others have IVF coverage only after a certain number of IUIs. Some have medication coverage but not procedure coverage. Before choosing a plan, request a written cost estimate for each pathway: IUI with oral medication, IUI with injectable medication, IVF without PGT-A, IVF with PGT-A, frozen embryo transfer, and embryo storage. Ask what is included and what is billed separately.

The most expensive path is often the one that is not planned: repeated IUIs without reassessment, followed by rushed IVF, followed by confusion about whether to test embryos, followed by delayed transfer. A clear roadmap can reduce both emotional and financial waste.

The bottom line

After 38, IUI may still have a role, but it should usually be a short, carefully selected strategy rather than an open-ended plan. Its lower upfront cost is appealing, yet the lower success rate per cycle and lack of embryo information can make it less efficient when time is limited. IVF costs more and requires more medical intervention, but it offers higher per-attempt efficiency for many patients, more diagnostic insight, the possibility of embryo freezing, and access to PGT-A when appropriate.

The best choice depends on age, ovarian reserve, sperm quality, tubal status, diagnosis, miscarriage history, family size goals, finances, emotional readiness, and personal values. For a 38-year-old with good ovarian reserve and no major infertility factors, a brief IUI trial may be reasonable. For a 40-year-old with diminished ovarian reserve, prior losses, or a desire for PGT-A, IVF may offer a better balance of time and success. For patients over 42, counseling should be especially realistic about the low probability of IUI success and the possible need to consider multiple IVF retrievals, donor eggs, or alternative family-building paths.

The central message is simple: after 38, time is a fertility treatment variable. The least expensive option today is not always the most cost-effective option in the long run. A thoughtful decision should weigh not only dollars, but also months, embryo quality, miscarriage risk, future family goals, and the value of knowing more sooner.

This article is for general education and does not replace individualized medical advice. Success rates and recommendations vary by clinic and patient situation. Please consult a reproductive endocrinologist or fertility specialist for a personalized evaluation and treatment plan.